Results

1–10 of 12 results for David A. Eichenbaum

ARCHER II, a Phase 3 Randomized Clinical Trial of ANX007 in Patients With Dry AMD and GA: Study Design andRationale Informed by Outcomes From ARCHER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2025
Efficacy and Safety of Anti-High Temperature Requirement A1 aHtrA1 Fab in Geographic Atrophy GA Secondary to AMD GAllego Phase 2 Randomized Trial
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2023
Expert Panel: Pegcetacoplan Safety
Andre J. Witkin, MD
David A. Eichenbaum, MD, FASRS
Samuel Anthony Minaker, MD, MSc
Janani Singaravelu, MS, MD
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2024
Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results of the Phase 3 YOSEMITE and RHINE Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2022
Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2021
Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) End of Study Results
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2020
It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD
David A. Eichenbaum, MD, FASRS
On Demand Cases, Courses, and Papers
2019
Inhibition of Complement C3 in GA with NGM621: Phase 1 Study Results
David A. Eichenbaum, MD, FASRS
Updates from the Field
2021
Response to Ranibizumab of Eyes With Pigment Epithelial Detachments, Including Eyes That Developed RPE Tears: Data From the HARBOR Study
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2016
Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration Across Key Clinical Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2018